MGNX vs. SANA, TYRA, SEPN, REPL, CRON, AVDL, IMTX, PLRX, BCAX, and PRTA
Should you be buying MacroGenics stock or one of its competitors? The main competitors of MacroGenics include Sana Biotechnology (SANA), Tyra Biosciences (TYRA), Septerna (SEPN), Replimune Group (REPL), Cronos Group (CRON), Avadel Pharmaceuticals (AVDL), Immatics (IMTX), Pliant Therapeutics (PLRX), Bicara Therapeutics (BCAX), and Prothena (PRTA). These companies are all part of the "pharmaceutical products" industry.
MacroGenics vs.
MacroGenics (NASDAQ:MGNX) and Sana Biotechnology (NASDAQ:SANA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.
In the previous week, Sana Biotechnology had 9 more articles in the media than MacroGenics. MarketBeat recorded 10 mentions for Sana Biotechnology and 1 mentions for MacroGenics. MacroGenics' average media sentiment score of 0.93 beat Sana Biotechnology's score of 0.42 indicating that MacroGenics is being referred to more favorably in the media.
MacroGenics received 406 more outperform votes than Sana Biotechnology when rated by MarketBeat users. Likewise, 62.28% of users gave MacroGenics an outperform vote while only 60.61% of users gave Sana Biotechnology an outperform vote.
MacroGenics has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.
Sana Biotechnology has a net margin of 0.00% compared to MacroGenics' net margin of -69.07%. Sana Biotechnology's return on equity of -84.22% beat MacroGenics' return on equity.
MacroGenics has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500. Comparatively, Sana Biotechnology has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.
96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 11.3% of MacroGenics shares are owned by company insiders. Comparatively, 31.1% of Sana Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
MacroGenics presently has a consensus price target of $7.63, suggesting a potential upside of 154.17%. Sana Biotechnology has a consensus price target of $14.25, suggesting a potential upside of 350.95%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe Sana Biotechnology is more favorable than MacroGenics.
Summary
MacroGenics beats Sana Biotechnology on 10 of the 18 factors compared between the two stocks.
Get MacroGenics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MacroGenics Competitors List
Related Companies and Tools
This page (NASDAQ:MGNX) was last updated on 1/18/2025 by MarketBeat.com Staff
Free MGNX Stock Alerts